Is COMPASS Pathways plc (CMPS) A Good Stock To Buy Now?

Is CMPS a good stock to buy? We came across a bullish thesis on COMPASS Pathways plc on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on CMPS. COMPASS Pathways plc’s share was trading at $11.26 as of June 9th.

Copyright: dolgachov / 123RF Stock Photo

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. CMPS is transitioning from a clinical-stage research company into a commercial-scale pharmaceutical platform, a shift the market continues to undervalue despite significant de-risking of its lead asset COMP360.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

Its core investment thesis is anchored in the successful Phase 3 clinical program, where COMP360 demonstrated statistically significant reductions in depressive symptoms, supported by a rolling FDA New Drug Application that has materially reduced regulatory risk.

With crystalline psilocybin patents extending to 2040 and integration into established interventional psychiatry infrastructure, the company has built a defensible moat that positions it ahead of broader psychedelic peers. The treatment is designed to disrupt rigid neural circuitry through 5-HT2A receptor activation, enabling durable neuroplasticity and creating a differentiated episodic model versus chronic antidepressant therapies.

Phase 3 results across COMP005 and COMP006 showed clinically meaningful MADRS improvements with durable response signals and a strong safety profile, including low serious adverse event rates. These data support a high probability of regulatory approval and underpin a base-case valuation framework that suggests significant upside relative to the current share price.

The addressable market for treatment-resistant depression is expanding into a multi-billion-dollar opportunity, with Compass positioned to compete directly against existing therapies such as Spravato while offering potentially longer-lasting effects.

Strategically, the company is viewed as an attractive acquisition target for large pharmaceutical players seeking CNS exposure, with potential interest from AbbVie, AstraZeneca, and Johnson & Johnson. Overall, Compass Pathways represents a high-conviction opportunity with $19 to $22 price targets and substantial upside as commercialization approaches into 2027 period.

Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted Casgevy commercialization, strong cash backing, and multi-platform gene-editing upside across oncology and cardiovascular programs. CRSP’s stock price has appreciated by approximately 25.65% since our coverage. BioEquity Watch shares a similar bullish view but emphasizes Compass Pathways’ (CMPS) late-stage regulatory de-risking and psychiatry-focused pipeline rather than gene-editing expansion.